SuPAR and PAI-1 in critically ill, mechanically ventilated patients

Area of Science:

• Biochemistry
• Critical Care Medicine
• Biomarker Discovery

Background:

• Soluble urokinase plasminogen activator receptor (suPAR) and plasminogen activator inhibitor 1 (PAI-1) are involved in the coagulation-fibrinolysis pathway.
• Both suPAR and PAI-1 have been investigated as potential biomarkers for disease severity.

Purpose of the Study:

• To evaluate suPAR and PAI-1 as predictors of mortality, acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), sepsis, and renal replacement therapy (RRT).
• To assess these biomarkers in both operative and non-operative mechanically ventilated patients.

Main Methods:

• Prospective, multicenter, observational study design.
• Collection of blood samples and intensive care data from mechanically ventilated patients.
• Utilized receiver operating characteristic (ROC) analysis, logistic regression, and Kaplan-Meier analysis.

Main Results:

• Baseline suPAR levels were significantly higher in ventilated patients compared to healthy volunteers.
• suPAR demonstrated predictive value for 90-day mortality, sepsis, ALI/ARDS, and RRT in non-operative patients.
• The predictive value of PAI-1 for these outcomes was found to be negligible.

Conclusions:

• In non-operative ventilated patients, suPAR concentration is a significant predictor of survival and mortality.
• Elevated suPAR levels may serve as an early warning for acute renal failure, indicating a need for RRT.
• suPAR could potentially be utilized for screening patients who may have a favorable survival prognosis.